Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFP + high-dose methylprednisolone + rituximab for ultra-high-risk chronic lymphocytic leukemia
ChiCTR-ONC-12002442Phase 3Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fresh-frozen plasma, methylprednisolone and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: overall response rate and safety and toxicity. Started Jan 2012; status: completed.
02
Drugs
fresh-frozen plasmamethylprednisolonerituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR-ONC-12002442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002442.